期刊
BLOOD
卷 121, 期 11, 页码 1982-1985出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-08-448563
关键词
-
类别
资金
- Celgene Corp
- Leukemia & Lymphoma Society SCOR grant
- National Institutes of Health National Cancer Institute [CA109260-01]
- Clinical and Translational Science Center at Weill Cornell Medical College [UL1-RR024996]
The combination of clarithromycin, lenalidomide, and dexamethasone (BiRd) was evaluated as therapy for treatment-naive symptomatic multiple myeloma (MM), with overall response at 2 years of 90%. We reviewed the long-term follow-up of initial BiRd therapy. Seventy-two patients were given dexamethasone 40 mg weekly, clarithromycin 500 mg twice daily, and lenalidomide 25 mg daily on days 1 to 21 of a 28-day cycle. After a median follow-up of 6.6 years, overall response rates were 93%, with a very good partial response or better of 68%. Median progression-free survival was 49 months. Evaluation for the development of second primary malignancies (SPMs) was conducted, and no increase in incidence was noted in our cohort of patients who received frontline immunomodulatory therapy. BiRd remains a highly potent and safe regimen for frontline therapy in patients with MM without apparent increase in risk of SPMs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据